Florence, March 10, 2025
A Major Milestone in Cytology Technology Adoption
Hospitex, the Italian subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) and a leader in the production of medical devices for cytology, has secured a major public tender with the Ecclesiastical Entity F. Miulli Regional General Hospital. This milestone marks a significant step in the adoption of Hospitex’s advanced cytology technology within the Pathological Anatomy Department.
F. Miulli Hospital: A National Oncology Reference Center
F. Miulli Regional General Hospital, located in Bari, is a national reference center for the medical and surgical treatment of complex tumors. In line with the Puglia Region’s directives, it hosts the ONCOLOGY ORIENTATION CENTER, an excellence hub that fosters collaboration among specialists through the sharing of protocols and procedures for increasingly effective and sustainable oncology management.
Excellence in Pathological Anatomy and Cytology
The hospital’s Department of Pathological Anatomy conducts histological, cytological, immunohistochemical, and molecular diagnostic tests, making it a national center of excellence in cytology.
Hospitex’s Advanced Cytology Technology
The awarded contract includes the complete supply of Hospitex’s Cytofast LBC (Liquid-Based Cytology) system and its patented BLOCKfast Cell Block technology for the next five years. This innovative solution will be used not only for cervical cytology but also for challenging organ samples such as the thyroid, lungs, bronchoalveolar lavages, and breast tissue, ensuring optimal specimen preparation for pathological diagnosis.
Strategic and Financial Impact of the Agreement
With a base tender value of €116,000, the long-term impact of this agreement will extend beyond the initial investment, generating recurring revenue through the ongoing consumption of reagents. The installation of Hospitex’s technology at F. Miulli Hospital further strengthens the company’s market presence and the growing adoption of its cytology solutions.
Future Innovations: Digital Pathology and FISH Integration
Looking ahead, Hospitex is developing new solutions for digital pathology and integrating its technology with FISH (Fluorescence In Situ Hybridization) for second-level diagnostics. These advancements aim to further enhance diagnostic accuracy and efficiency in pathology laboratories worldwide.
